China Shineway Pharmaceutical Group Limited Tangible Net Worth Ratio
China Shineway Pharmaceutical Group Limited tangible net worth ratio. China Shineway Pharmaceutical Group Limited (C1S) has a Tangible Net Worth Ratio of 99.8% as of December 2025. This metric is calculated by deducting intangible assets (€15.72 Million) from net assets (€8.06 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Check China Shineway Pharmaceutical Group Limi PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of China Shineway Pharmaceutical Group Limited (2013–2025)
Tangible net worth ratio of China Shineway Pharmaceutical Group Limited from 2013 to 2025. This chart shows how China Shineway Pharmaceutical Group Limited's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at 99.8%, reflecting net assets of €8.06 Billion with intangible assets of €15.72 Million EUR. See C1S working capital ratio to evaluate short-term liquidity relative to the company's equity base.
China Shineway Pharmaceutical Group Limited Tangible Net Worth Ratio by Year (2013–2025)
China Shineway Pharmaceutical Group Limited tangible net worth ratio by year from 2013 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market cap of China Shineway Pharmaceutical Group Limi.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 99.8% | €8.06 Billion | €15.72 Million | €10.78 Billion | ▲ +0.1 pp |
| 2024 | 99.7% | €7.47 Billion | €23.32 Million | €10.04 Billion | ▲ +0.2 pp |
| 2023 | 99.5% | €7.03 Billion | €32.79 Million | €9.57 Billion | ▲ +0.3 pp |
| 2022 | 99.3% | €6.38 Billion | €47.35 Million | €8.23 Billion | ▲ +0.4 pp |
| 2021 | 98.9% | €5.90 Billion | €66.43 Million | €7.20 Billion | ▼ -0.5 pp |
| 2020 | 99.4% | €5.79 Billion | €36.96 Million | €7.21 Billion | ▲ +3.7 pp |
| 2019 | 95.7% | €5.78 Billion | €248.27 Million | €7.13 Billion | ▲ +0.7 pp |
| 2018 | 95.0% | €5.77 Billion | €287.92 Million | €6.73 Billion | ▲ +0.3 pp |
| 2017 | 94.7% | €5.82 Billion | €307.96 Million | €6.67 Billion | ▲ +0.9 pp |
| 2016 | 93.8% | €5.63 Billion | €348.35 Million | €6.47 Billion | ▲ +1.1 pp |
| 2015 | 92.7% | €5.30 Billion | €388.74 Million | €6.15 Billion | ▼ -6.9 pp |
| 2014 | 99.5% | €4.89 Billion | €23.29 Million | €5.91 Billion | ▼ -0.5 pp |
| 2013 | 100.0% | €4.43 Billion | €518.00K | €5.74 Billion | — |